94 related articles for article (PubMed ID: 19689997)
21. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.
Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T
Biol Blood Marrow Transplant; 2008 Mar; 14(3):268-81. PubMed ID: 18275893
[TBL] [Abstract][Full Text] [Related]
22. Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways.
Menschikowski M; Hagelgans A; Eisenhofer G; Siegert G
Exp Cell Res; 2009 Sep; 315(15):2673-82. PubMed ID: 19467228
[TBL] [Abstract][Full Text] [Related]
23. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms.
Palomo M; Diaz-Ricart M; Carbo C; Rovira M; Fernandez-Aviles F; Escolar G; Eissner G; Holler E; Carreras E
Biol Blood Marrow Transplant; 2009 May; 15(5):537-46. PubMed ID: 19361745
[TBL] [Abstract][Full Text] [Related]
24. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation.
Inbal A; Lubetsky A; Shimoni A; Dardik R; Sela BA; Eskaraev R; Levi I; Tov NS; Nagler A
Bone Marrow Transplant; 2004 Sep; 34(5):459-63. PubMed ID: 15247931
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
27. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation.
Remberger M; Svahn BM; Hentschke P; Löfgren C; Ringdén O
Bone Marrow Transplant; 1999 Oct; 24(8):823-30. PubMed ID: 10516691
[TBL] [Abstract][Full Text] [Related]
28. The cytokines IL-1beta and IL-1 receptor antagonist, IL-2 and IL-2 soluble receptor-alpha, IL-6 and IL-6 soluble receptor, TNF-alpha and TNF soluble receptor I, and IL10 in drained and systemic blood after major orthopaedic surgery.
Krohn CD; Reikerås O; Aasen AO
Eur J Surg; 1999 Feb; 165(2):101-9. PubMed ID: 10192566
[TBL] [Abstract][Full Text] [Related]
29. Psychological and cytokine changes in children and adolescents undergoing hematopoietic stem cell transplantation.
Munitz-Shenkar D; Krulik T; Peretz C; Shiloh R; Elhasid R; Toren A; Weizman A
Eur Neuropsychopharmacol; 2007 Jan; 17(1):58-63. PubMed ID: 16844356
[TBL] [Abstract][Full Text] [Related]
30. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
[TBL] [Abstract][Full Text] [Related]
31. Ocular findings after allogeneic hematopoietic stem cell transplantation.
Tabbara KF; Al-Ghamdi A; Al-Mohareb F; Ayas M; Chaudhri N; Al-Sharif F; Al-Zahrani H; Mohammed SY; Nassar A; Aljurf M
Ophthalmology; 2009 Sep; 116(9):1624-9. PubMed ID: 19729097
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
Iguchi A; Kobayashi R; Yoshida M; Kobayashi K; Matsuo K; Kitajima I; Maruyama I
Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
[TBL] [Abstract][Full Text] [Related]
33. Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation.
Nomura S; Ishii K; Inami N; Uoshima N; Ishida H; Yoshihara T; Kitayama H; Hayashi K
Transpl Immunol; 2007 Nov; 18(2):115-21. PubMed ID: 18005854
[TBL] [Abstract][Full Text] [Related]
34. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
[TBL] [Abstract][Full Text] [Related]
35. Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population.
Laguila Visentainer JE; Lieber SR; Lopes Persoli LB; Dutra Marques SB; Vigorito AC; Penteado Aranha FJ; de Brito Eid KA; Oliveira GB; Martins Miranda EC; Bragotto L; de Souza CA
Cytokine; 2005 Nov; 32(3-4):171-7. PubMed ID: 16243534
[TBL] [Abstract][Full Text] [Related]
36. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
[TBL] [Abstract][Full Text] [Related]
37. Elevated serum cytokine levels are associated with human herpesvirus 6 reactivation in hematopoietic stem cell transplantation recipients.
Fujita A; Ihira M; Suzuki R; Enomoto Y; Sugiyama H; Sugata K; Suga S; Asano Y; Yagasaki H; Kojima S; Matsumoto K; Kato K; Yoshikawa T
J Infect; 2008 Sep; 57(3):241-8. PubMed ID: 18662831
[TBL] [Abstract][Full Text] [Related]
38. Introduction of the oncological pediatric risk of mortality score (O-PRISM) for ICU support following stem cell transplantation in children.
Schneider DT; Lemburg P; Sprock I; Heying R; Göbel U; Nürnberger W
Bone Marrow Transplant; 2000 May; 25(10):1079-86. PubMed ID: 10828869
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation.
Nakamae H; Hino M; Akahori M; Terada Y; Yamane T; Ohta K; Hayashi T; Tsumura K
Am J Hematol; 2004 May; 76(1):1-7. PubMed ID: 15114589
[TBL] [Abstract][Full Text] [Related]
40. Cytokines and soluble tumour necrosis factor I receptor levels during pretransplant conditioning in allogeneic stem-cell transplantation.
Andersen J; Heilmann C; Jacobsen N; Bendtzen K; Müller K
Int Immunopharmacol; 2005 Jan; 5(1):67-71. PubMed ID: 15589461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
